Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Type I collagen alpha-1 chain, encoded by the COL1A1 gene, is the principal protein subunit of type I collagen, the most abundant collagen in the human body and a major component of bone, skin, tendon, and other connective tissues[1][3][4][5]. The protein forms a triple-helical structure by assembling with another alpha-1 chain and one alpha-2 chain (COL1A2) to build fibrillar collagen networks that provide strength, rigidity, and elasticity to tissues[1][4][5]. Mutations in COL1A1 have been linked to a range of connective tissue disorders such as osteogenesis imperfecta, several forms of Ehlers-Danlos syndrome, and predispositions to osteoporosis and disc disease[1][3]. The intact protein is essential for normal skeletal development and connective tissue integrity, while its dysfunction results in tissue fragility and disease.
Indirect: Inhibition of bone resorption/matrix turnover (e.g., bisphosphonates decrease osteoclast activity reducing fracture risk in osteogenesis imperfecta) Indirect: Promotion of bone formation (e.g., teriparatide stimulates osteoblasts) Potential experimental: Reduction of fibrotic collagen synthesis (anti-fibrotic drugs)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Type I collagen alpha-1 chain (COL1A1).